Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial
Authors:
Open Access
- 22 August 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 33 (10) , 1063-1074
Abstract
ObjectivesThis Phase 1 trial was planned to investigate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of a single dose of riliprubart in healthy East-Asian adult participants.MethodsA single-center, parallel-group, randomized, open-label, single-dose study was performed to evaluate the PK, PD, safety, and tolerability of riliprubart (50 mg/kg intravenous [IV] or 600 mg subcutaneous [SC]) in 37 healthy East-Asian (Chinese, Japanese, and Korean) participants.ResultsRiliprubart was slowly absorbed after SC administration (median tmax: 7.01-10.48 days) and showed a long half-life after IV or SC administration (mean: 9.52-11.0 weeks), with a bioavailability of 74.6% after SC administration. The PD profiles, which are evaluated by classical complement pathway activity or CH50, were similar and largely overlapped across East-Asian participants after a single IV or SC dose. Riliprubart was safe and well tolerated in participants following a single IV or SC dose.ConclusionsRiliprubart was safe and well tolerated and demonstrated favorable PK and PD profiles in healthy East-Asian participants following a single IV or SC dose. These results are comparable to first-in-human study results from non-East-Asian participants and support the same dosing regimen of riliprubart for global simultaneous clinical development.Clinical trial registrationThis trial is registered at https://cris.nih.go.kr (identifier: KCT0006571).Keywords
Funding Information
- Sanofi
This publication has 24 references indexed in Scilit:
- An innovative phase 2 proof‐of‐concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathyJournal of the Peripheral Nervous System, 2023
- Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1sClinical Immunology, 2023
- First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitorClinical and Translational Science, 2023
- FDA approves second BCMA-targeted CAR-T cell therapyNature Reviews Drug Discovery, 2022
- Complement in neurological disorders and emerging complement-targeted therapeuticsNature Reviews Neurology, 2020
- Clinical promise of next-generation complement therapeuticsNature Reviews Drug Discovery, 2019
- A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement PathwayClinical Pharmacology & Therapeutics, 2018
- Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection—results from a first-in-patient phase 1 trialAmerican Journal of Transplantation, 2018
- The complement systemCell and tissue research, 2010
- The complement system in the peripheral nerve: Friend or foe?Molecular Immunology, 2008